Blog

Oct 28, 2024, 10:54

SPCC – Brian Druker reflects on the key milestones of his life and career

SPCC (Sharing Progress in Cancer Care) shared on Linkedin:

”Have you already watched Aleksandra Filipovic’s inspirational interview with Brian Druker, the esteemed director of the OHSU Knight Cancer Institute?

Known for his groundbreaking work in cancer research, Druker developed Gleevec, a targeted therapy that revolutionised the treatment of chronic myeloid leukemia (CML) by attacking cancer cells while preserving healthy ones.

In the interview, Druker reflects on the key milestones of his life and career, from his early days to his present work.

Every new drug has a human who has championed it to existence, who persevered, who believed. Who knew the ‘Why’ and therefore found the ‘How’.

Watch it now.”

Aleksandra Filipovic Brian Druker cancer Cancer research Chronic myeloid leukemia (CML) CML OHSU Knight Cancer Institute OncoDaily Oncology SPCC (Sharing Progress in Cancer Care)

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers